The Latest in Rheum for Action

Rheumatology News

Abuse of the Safety-Net 340B Drug Pricing Program: Why Should Physicians Care?

November 18, 2024

Business of Medicine

Rheumatology News

‘Reform School’ for Pharmacy Benefit Managers: How Might Legislation Help Patients?

September 17, 2024

Business of Medicine

Rheumatology News

Fed Worker Health Plans Ban Maximizers and Copay Accumulators: Why Not for the Rest of the US?

July 29, 2024

Business of Medicine

Rheumatology News

Don’t Leave CVD Risk in RA Undertreated Despite Unresolved Questions

May 16, 2024

Rheumatoid Arthritis

Rheumatology News

Specialists Are ‘Underwater’ With Some Insurance-Preferred Biosimilars

May 16, 2024

Rheumatology News

ERISA Health Plan Lawsuits: Why Should We Care?

March 15, 2024

Business of Medicine

Rheumatology News

Biosimilar Business Deals Keep Up ‘Musical Chairs’ Game of Formulary Construction

January 17, 2024

Business of Medicine

Rheumatology News

Prescription drug affordability boards: Another quick fix with unintended consequences?

November 17, 2023

Business of Medicine

Rheumatology News

Insurer’s foray into AI-based ‘shared savings’ program creates ethical problems

September 20, 2023

Business of Medicine

Rheumatology News

In-office infusions at risk with new Medicare Part B reimbursement recommendation

July 6, 2023

Business of Medicine

Rheumatology News

Getting a white-bagging exemption: A win for the patient, employer, and rheumatologist

May 2, 2023

Business of Medicine

Rheumatology News

A little education goes a long way for advocacy

March 16, 2023

Business of Medicine

Rheumatology News

Unintended consequences of perfectly good programs and policies

January 18, 2023

Business of Medicine

Rheumatology News

Use 2022’s advocacy successes and frustrations as a catalyst for the new year

November 14, 2022

Business of Medicine

Rheumatology News

Employers’ self-funded health plans can leave rheumatology patients vulnerable

September 20, 2022

Business of Medicine